Literature DB >> 27267910

Phenotypic and Signaling Consequences of a Novel Aberrantly Spliced Transcript FGF Receptor-3 in Hepatocellular Carcinoma.

Ke Li1, Baiyong Shen1, Xi Cheng1, Ding Ma1, Xiaoqian Jing1, Xinyu Liu1, Weiping Yang1, Chenghong Peng2, Weihua Qiu2.   

Abstract

Fibroblast growth factor receptor 3 (FGFR3) plays important roles in cell proliferation, differentiation, and angiogenesis. FGFR3 is abnormally upregulated in hepatocellular carcinoma (HCC), where it correlates positively with clinicopathologic index, HCC differentiation, and advanced nuclear grade. In this study, we describe an aberrantly spliced transcript of FGFR3, termed FGFR3Δ7-9, was identified as a high frequency even in HCC. FGFR3Δ7-9 lacks exons encoding the immunoglobulin-like III domain and promoted the proliferation, migration, and metastasis of HCC cells both in vitro and in vivo Coimmunoprecipation and surface plasmon resonance assays demonstrated that the binding affinity of the aberrant FGFR3Δ7-9 receptor to FGFs was significantly higher than wild-type FGFR3IIIc Furthermore, FGFR3Δ7-9 could be self-activated by homodimerization and autophosphorylation even in the absence of ligand. Finally, FGFR3Δ7-9 more potently induced phosphorylation of the ERK and AKT kinases, leading to abnormal downstream signaling through the ERK and PI3K/AKT/mTOR pathways. FGFR3Δ7-9 also upregulated the metastasis-associated molecules Snail, MMP-9, and downregulated E-cadherin, which associated directly with FGFR3Δ7-9 Thus, as a ligand-dependent or -independent receptor, FGFR3Δ7-9 exerted multiple potent oncogenic functions in HCC cells, including proliferation, migration, and lung metastatic capacity. Overall, FGFR3 mRNA missplicing in HCC contributes significantly to its malignant character, with implications for therapeutic targeting. Cancer Res; 76(14); 4205-15. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27267910     DOI: 10.1158/0008-5472.CAN-15-3385

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  A Novel FGFR3 Splice Variant Preferentially Expressed in African American Prostate Cancer Drives Aggressive Phenotypes and Docetaxel Resistance.

Authors:  Jacqueline Olender; Bi-Dar Wang; Travers Ching; Lana X Garmire; Kaitlin Garofano; Youngmi Ji; Tessa Knox; Patricia Latham; Kenneth Nguyen; Johng Rhim; Norman H Lee
Journal:  Mol Cancer Res       Date:  2019-07-02       Impact factor: 5.852

2.  FGFR3 promotes angiogenesis-dependent metastasis of hepatocellular carcinoma via facilitating MCP-1-mediated vascular formation.

Authors:  Xinyu Liu; Xiaoqian Jing; Xi Cheng; Ding Ma; Zhijian Jin; Weiping Yang; Weihua Qiu
Journal:  Med Oncol       Date:  2016-04-04       Impact factor: 3.064

3.  Up-regulation of chemokine receptor CCR4 is associated with Human Hepatocellular Carcinoma malignant behavior.

Authors:  Xi Cheng; Huo Wu; Zhi-Jian Jin; Ding Ma; Stanley Yuen; Xiao-Qian Jing; Min-Min Shi; Bai-Yong Shen; Cheng-Hong Peng; Ren Zhao; Wei-Hua Qiu
Journal:  Sci Rep       Date:  2017-09-28       Impact factor: 4.379

4.  Pseudomonas aeruginosa-mannose-sensitive hemagglutinin inhibits pancreatic cancer cell proliferation and induces apoptosis via the EGFR pathway and caspase signaling.

Authors:  Xi Cheng; Bingrui Wang; Zhijian Jin; Ding Ma; Weiping Yang; Ren Zhao; Xiaoqian Jing; Baiyong Shen; Chenghong Peng; Weihua Qiu
Journal:  Oncotarget       Date:  2016-11-22

Review 5.  Advances of Fibroblast Growth Factor/Receptor Signaling Pathway in Hepatocellular Carcinoma and its Pharmacotherapeutic Targets.

Authors:  Haijun Wang; Jie Yang; Ke Zhang; Jia Liu; Yushan Li; Wei Su; Na Song
Journal:  Front Pharmacol       Date:  2021-04-15       Impact factor: 5.810

Review 6.  Impact of Alternative Splicing Variants on Liver Cancer Biology.

Authors:  Jose J G Marin; Maria Reviejo; Meraris Soto; Elisa Lozano; Maitane Asensio; Sara Ortiz-Rivero; Carmen Berasain; Matias A Avila; Elisa Herraez
Journal:  Cancers (Basel)       Date:  2021-12-21       Impact factor: 6.639

7.  Identification and validation of critical alternative splicing events and splicing factors in gastric cancer progression.

Authors:  Haoran Feng; Zhijian Jin; Kun Liu; Yi Peng; Songyao Jiang; Changgang Wang; Jiele Hu; Xiaoyun Shen; Weihua Qiu; Xi Cheng; Ren Zhao
Journal:  J Cell Mol Med       Date:  2020-09-16       Impact factor: 5.310

8.  Interaction of FGF9 with FGFR3-IIIb/IIIc, a putative driver of growth and aggressive behaviour of hepatocellular carcinoma.

Authors:  Jakob Paur; Maximilian Valler; Rebecca Sienel; Karin Taxauer; Klaus Holzmann; Brigitte Marian; Andreas Unterberger; Thomas Mohr; Walter Berger; Andja Gvozdenovich; Johannes Schimming; Michael Grusch; Bettina Grasl-Kraupp
Journal:  Liver Int       Date:  2020-06-17       Impact factor: 5.828

9.  FGFR3△7-9 promotes tumor progression via the phosphorylation and destabilization of ten-eleven translocation-2 in human hepatocellular carcinoma.

Authors:  Zhijian Jin; Haoran Feng; Juyong Liang; Xiaoqian Jing; Qiwu Zhao; Ling Zhan; Baiyong Shen; Xi Cheng; Liping Su; Weihua Qiu
Journal:  Cell Death Dis       Date:  2020-10-23       Impact factor: 8.469

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.